# Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)

> **NCT04924101** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 126 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **BIOLOGICAL:** MK-4830
- **BIOLOGICAL:** Boserolimab
- **DRUG:** Lenvatinib
- **DRUG:** Etoposide
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT04924101
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-15
- **Primary completion:** 2025-06-23
- **Final completion:** 2025-06-23
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2025-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04924101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04924101, "Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04924101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*